Akut induceret diabetes mellitus hos en patient i behandling for metastaserende malignt melanom
Engelsk titel: Acutely induced diabetes mellitus in a 63-year-old female after treatment with ipilimumab for metastatic melanoma
Läs online
Författare:
Bisgaard Jörgensen, Line
;
Yderstraede, Knud
Email: line.bisgaard.joergensen@rsyd.dk
Språk: Dan
Antal referenser: 5
Dokumenttyp:
Fallbeskrivning
UI-nummer: 18020331
Sammanfattning
Immune checkpoint inhibitors have improved survival rate in patients with advanced melanoma, but also have the potential to induce several adverse events. We report on a 63-year-old woman who had advanced melanoma and was admitted with diabetic ketoacidosis, which had occurred upon treatment with ipilimumab. On admission, the C-peptide level was low, and the HbA1c concentration was 50 mmol/l indicating a rapid onset of the disease. The patient had also been diagnosed with thyroiditis. Diabetes mellitus is a rare and serious side effect of treatment with ipilimumab, and we recommend being aware of this due to the rapid course.